aripiprazole has been researched along with Recrudescence in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (34.29) | 29.6817 |
| 2010's | 19 (54.29) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| García Dorado, M; Gutiérrez-Rojas, L; López Rengel, PM; Sánchez-Alonso, S | 1 |
| Dorozhenok, IY | 1 |
| Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y | 1 |
| Blumberger, DM; Buchalter, ELF; Dixon, D; Karp, JF; Lenze, EJ; Miller, JP; Mulsant, BH; Oughli, HA; Reynolds, CF | 1 |
| Lin, Z; Xuan, J | 1 |
| Biagi, E; Brambilla, G; Capuzzi, E; Clerici, M; Colmegna, F; Mascarini, A; Ornaghi, A; Santambrogio, J | 1 |
| Frampton, JE | 1 |
| Barreto, S; Kar, N | 1 |
| Cheng, Y; Jiang, K; Li, Q; Lin, Z; Xuan, J; Zhang, Y; Zhao, J | 1 |
| Angeletti, G; Brugnoli, R; Cuomo, I; De Filippis, S; Del Casale, A; Ferracuti, S; Giordano, G; Girardi, P; Kotzalidis, GD; Mazzarini, L; Rapinesi, C; Sani, G | 1 |
| Grossman, F; Hassan, M; Meyer, K; O'Day, K; Rajagopalan, K | 1 |
| Begley, A; Butters, MA; Koenig, AM; Ogbagaber, S; Reynolds, CF; Wahed, AS | 1 |
| Baker, RA; Carson, WH; Eramo, A; Fleischhacker, WW; Jin, N; Johnson, BR; Kane, JM; McQuade, RD; Perry, PP; Peters-Strickland, T; Sanchez, R; Walling, D | 1 |
| Anderson, SJ; Begley, AE; Blumberger, DM; Butters, MA; Dew, MA; Karp, JF; Lenze, EJ; Mulsant, BH; Newcomer, JW; Reynolds, CF; Stack, JA | 1 |
| Bose, A; Citrome, L; Claxton, A; Du, Y; Ehrich, EW; Risinger, R; Silverman, BL; Stankovic, S; Zummo, J | 1 |
| Crowe, L; Loebel, A; Rajagopalan, K; Squirrell, D; Trueman, D | 1 |
| Amatniek, J; Calabrese, JR; Carson, WH; Cox, K; Hertel, P; Jin, N; Johnson, B; McQuade, RD; Nyilas, M; Perry, P; Salzman, PM; Sanchez, R; Such, P | 1 |
| Carlson, BX; Eudicone, J; Marcus, RN; Masand, PS; McQuade, RD; Pikalov, A; Vester-Blokland, E | 1 |
| Elkashef, A; Hanson, G; Tiihonen, J; Vocci, F; White, J; Wickes, W | 1 |
| Haffejee, S; Santosh, PJ | 1 |
| Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD | 1 |
| Manoj, P; Skopek, M | 1 |
| Bowden-Jones, H; Kitchenham, N; Smith, N | 1 |
| Grohmann, R; Holl, AK; Letmaier, M; Painold, A; Vergin, H | 1 |
| Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Liang, HY; Tang, CS; Wang, LJ; Wu, YY; Yeh, CB | 1 |
| Lin, CC; Lin, HY; Liu, CC | 1 |
| Perry, CL; Reeves, RR | 1 |
| Ali, M; Archibald, D; Carson, WH; Ingenito, G; Kasper, S; Lerman, MN; Marcus, R; McQuade, RD; Pigott, T; Saha, A | 1 |
| Adams, CE; El-Sayeh, HG; Morganti, C | 1 |
| Coffey, B; Jummani, R; Vito, J | 1 |
| Anolik, R; Johnson, RA; Kunkel, EJ; Mago, R | 1 |
| Chrzanowski, WK; Marcus, RN; McQuade, RD; Nyilas, M; Torbeyns, A | 1 |
| Liskow, BI; Moeller, KE; Shireman, TI | 1 |
| Ahuja, N; Lloyd, AJ | 1 |
| Amoretti, A; Di Lorenzo, R; Fiorini, F; Forghieri, M; Genedani, S; Rigatelli, M | 1 |
6 review(s) available for aripiprazole and Recrudescence
| Article | Year |
|---|---|
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections; Male; Middle Aged; Recurrence; Schizophrenia | 2017 |
Aripiprazole Lauroxil: A Review in Schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Injections, Intramuscular; Recurrence; Schizophrenia | 2017 |
Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Delayed-Action Preparations; Humans; Injections, Intramuscular; Male; Recurrence; Schizophrenia | 2019 |
Pharmacotherapy of methamphetamine addiction: an update.
Topics: Antipsychotic Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; Drug Therapy; Humans; Lobeline; Methamphetamine; Methylphenidate; Narcotic Antagonists; Nicotinic Agonists; Piperazines; Prevalence; Quinolones; Recurrence; Substance-Related Disorders | 2008 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evidence-Based Medicine; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2009 |
Aripiprazole for schizophrenia. Systematic review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Patient Compliance; Piperazines; Prolactin; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia; Treatment Outcome | 2006 |
9 trial(s) available for aripiprazole and Recrudescence
| Article | Year |
|---|---|
Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History.
Topics: Algorithms; Antidepressive Agents; Anxiety Disorders; Aripiprazole; Clinical Decision Rules; Comorbidity; Delayed-Action Preparations; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Likelihood Functions; Prospective Studies; Recurrence; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Young Adult | 2014 |
Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Recurrence; Treatment Outcome | 2015 |
Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Asia; Disease Progression; Europe; Female; Hostility; Humans; Injections, Intramuscular; Male; Middle Aged; Psychiatric Status Rating Scales; Psychomotor Agitation; Recurrence; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; United States; Young Adult | 2016 |
Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
Topics: Administration, Oral; Adult; Affect; Aripiprazole; Bipolar Disorder; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Male; Middle Aged; Recurrence; Substance Withdrawal Syndrome; Treatment Outcome | 2017 |
Criteria for defining symptomatic and sustained remission in bipolar I disorder: a post-hoc analysis of a 26-week aripiprazole study (study CN138-010).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Recurrence | 2008 |
Effectiveness of aripiprazole in adolescents and young adults with schizophrenia spectrum disorders: comparison of first-episode to recurrent psychosis.
Topics: Adolescent; Adolescent Behavior; Adult; Aripiprazole; Child; Female; Humans; Male; Piperazines; Psychotic Disorders; Quality of Life; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology | 2013 |
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Long-Term Care; Male; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2003 |
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Triglycerides | 2006 |
20 other study(ies) available for aripiprazole and Recrudescence
| Article | Year |
|---|---|
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Recurrence; Retrospective Studies; Schizophrenia; Spain | 2022 |
[Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)].
Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Quinolones; Recurrence; Schizophrenia | 2022 |
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones; Recurrence; Schizophrenia | 2023 |
Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.
Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; China; Computer Simulation; Cost-Benefit Analysis; Drug Delivery Systems; Humans; Medication Adherence; Olanzapine; Quality-Adjusted Life Years; Recurrence; Schizophrenia; Tablets | 2020 |
Psychosis, creativity and recovery: exploring the relationship in a patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Creativity; Female; Humans; Medication Adherence; Paranoid Behavior; Psychotic Disorders; Recurrence; Writing | 2018 |
Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
Topics: Antipsychotic Agents; Aripiprazole; China; Cost-Benefit Analysis; Drug Compounding; Health Resources; Humans; Medication Adherence; Models, Econometric; Olanzapine; Quality-Adjusted Life Years; Recurrence; Schizophrenia | 2019 |
Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus; Hospitalization; Humans; Isoindoles; Lurasidone Hydrochloride; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Piperazines; Quinolones; Recurrence; Schizophrenia; Thiazoles; United States | 2013 |
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Citalopram; Cognitive Dysfunction; Cyclohexanols; Dementia; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Venlafaxine Hydrochloride | 2014 |
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Financing, Personal; Humans; Lurasidone Hydrochloride; Markov Chains; Quality-Adjusted Life Years; Recurrence; Schizophrenia; Scotland; Wales | 2016 |
Treatment of alternating hemiplegia of childhood with aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Behavior Therapy; Child Behavior Disorders; Combined Modality Therapy; Dopamine Agonists; Female; Follow-Up Studies; Hemiplegia; Humans; Neurologic Examination; Piperazines; Quinolones; Recurrence | 2009 |
Hyperprolactinaemia during treatment with paliperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Galactorrhea; Humans; Hyperprolactinemia; Isoxazoles; Middle Aged; Paliperidone Palmitate; Patient Compliance; Piperazines; Prolactin; Psychotic Disorders; Pyrimidines; Quetiapine Fumarate; Quinolones; Recurrence; Schizophrenia, Paranoid; Young Adult | 2010 |
Pathological gambling and the treatment of psychosis with aripiprazole: case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Male; Piperazines; Quinolones; Recurrence; Schizophrenia | 2011 |
Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Combinations; Drug Interactions; Female; Haloperidol; Humans; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Recurrence; Risperidone | 2012 |
Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: dose-related phenomenon?
Topics: Aripiprazole; Bipolar Disorder; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Piperazines; Quinolones; Recurrence | 2012 |
Aripiprazole for sexually inappropriate vocalizations in frontotemporal dementia.
Topics: Antipsychotic Agents; Aripiprazole; Frontotemporal Dementia; Humans; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Sexual Behavior; Treatment Outcome; Verbal Behavior | 2013 |
Advanced pediatric psychopharmacology.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cannabinoids; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Humans; Male; Marijuana Abuse; Mental Status Schedule; Neuroleptic Malignant Syndrome; Patient Readmission; Piperazines; Prognosis; Psychoses, Substance-Induced; Quinolones; Recurrence; Social Environment; Thiazoles; Treatment Refusal | 2006 |
Recurrent priapism associated with use of aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Priapism; Quinolones; Recurrence; Schizophrenia, Paranoid | 2006 |
Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Cohort Studies; Female; Hospitalization; Humans; Male; Middle Aged; Piperazines; Quinolones; Recurrence; Retrospective Studies; Schizophrenia; Treatment Outcome | 2006 |
Aripiprazole and worsening of psychosis: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Disease Progression; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Recurrence | 2007 |
Aripiprazole: effectiveness and safety under naturalistic conditions.
Topics: Adult; Antipsychotic Agents; Anxiety; Aripiprazole; Female; Humans; Inpatients; Italy; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Recurrence; Retrospective Studies; Schizoid Personality Disorder; Schizophrenia, Paranoid; Schizotypal Personality Disorder; Sleep Initiation and Maintenance Disorders; Time Factors; Treatment Outcome | 2007 |